{{Rsnum
|rsid=4933824
|Gene=NRG3
|Chromosome=10
|position=83819125
|Orientation=plus
|GMAF=0.1175
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 92.9 | 7.1 | 0.0
| HCB | 81.8 | 17.5 | 0.7
| JPT | 82.9 | 16.2 | 0.9
| YRI | 38.8 | 49.0 | 12.2
| ASW | 59.6 | 33.3 | 7.0
| CHB | 81.8 | 17.5 | 0.7
| CHD | 85.3 | 14.7 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 52.7 | 41.8 | 5.5
| MEX | 93.1 | 6.9 | 0.0
| MKK | 74.2 | 23.9 | 1.9
| TSI | 87.3 | 11.8 | 1.0
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs4933824
|PubMedID=18521091
|Condition=Response to iloperidone treatment (QT prolongation)
|Gene=NRG3
|Risk Allele=T
|pValue=2.00E-006
|OR=NA
|95CI=
}}

{{PharmGKB
|RSID=rs4933824
|Name_s=
|Gene_s=NRG3
|Feature=
|Evidence=PubMed ID:18521091; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia (Initial Sample Size: 183 individuals; Replication Sample Size: NR; Risk Allele: rs4933824-T). This variant is associated with Response to iloperidone treatment (QT prolongation).
|Drugs=iloperidone
|Drug Classes=
|Diseases=Acquired Long QT Syndrome (aLQTS); congenital long QT syndrome; Long QT Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356590
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4933824
|overall_frequency_n=112
|overall_frequency_d=128
|overall_frequency=0.875
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=92
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}